Follow-On Biologics Under Eshoo’s Bill Not A “Viable Business,” Sandoz Says

No pharmaceutical company will develop follow-on biologics if anything close to the brand-friendly legislation introduced by Rep. Anna Eshoo, D-Calif., to create a regulatory pathway is passed by Congress, Sandoz Biopharmaceuticals head Hannes Teissl said